Type 2 diabetes – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Type 2 diabetes is a chronic progressive metabolic disorder, usually irreversible, that leads to impaired metabolism of carbohydrates, fats, and proteins because of a lack of, or ineffective use of, the hormone insulin. Three core pathophysiological processes combine to produce type 2 diabetes: insulin resistance, defective insulin secretion, and excess hepatic glucose production. The resulting hyperglycemia leads to excess insulin production, followed by a decline in the function and mass of pancreatic beta cells, leading to diabetes. For most diabetic and prediabetic patients, a high BMI (> 30) is the predetermining etiological factor for developing type 2 diabetes. A close link exists between the prevalence of insulin resistance and obesity. Vascular inflammation resulting from hyperglycemia is a critical factor in the emergence of complications in late-stage diabetes. Both macro- and microvasculature are affected, leading to retinopathy, neuropathy, nephropathy, and cardiovascular disease.

The prevalence rate of Type 2 diabetes varies from 8.5% to 11.8% of the population in the USA. However, the treated population is ~78% of the prevalent population.

The competitive landscape of Type 2 diabetes includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Type 2 diabetes across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Type 2 Diabetes Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Type 2 diabetes – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Exenatide         AstraZeneca     Phase 3

2          KBP-042           KeyBioscience AG         Phase 2

3          ORMD-0801     Oramed, Ltd.     Phase 3

4          Rivoglitazone    Daiichi Sankyo Co., Ltd. Phase 3

5          Ertugliflozin       Merck Sharp & Dohme Corp.     Phase 3

6          Bromocriptine mesylate VeroScience     Phase 1

7          efpeglenatide (SAR439977)       Hanmi Pharmaceutical   Phase 3

8          LY3209590       Eli Lilly and Company    Phase 3

9          ALT-801           Altimmune, Inc. Phase 1

10        YYC405            Yooyoung Pharmaceutical Co., Ltd.        Phase 3

Continued
 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more